Cover Image
市場調查報告書

類鴉片物質誘發性便秘治療市場:(µ類鴉片物質受體拮抗劑,氯離子通道活化劑,其他:固態,半固態,液狀):全球產業分析,規模,佔有率,成長,趨勢,及2015∼2023年的預測

Opioid Induced Constipation Treatment Market: (Mu-opioid Receptor Antagonist, Chloride Channel Activator, and Others; Solid, Semi-solid, and Liquid): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

出版商 Transparency Market Research 商品編碼 357104
出版日期 內容資訊 英文 91 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
類鴉片物質誘發性便秘治療市場:(µ類鴉片物質受體拮抗劑,氯離子通道活化劑,其他:固態,半固態,液狀):全球產業分析,規模,佔有率,成長,趨勢,及2015∼2023年的預測 Opioid Induced Constipation Treatment Market: (Mu-opioid Receptor Antagonist, Chloride Channel Activator, and Others; Solid, Semi-solid, and Liquid): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023
出版日期: 2016年04月01日 內容資訊: 英文 91 Pages
簡介

重度的慢性便秘是消費類鴉片物質的主要副作用,對傳統的便秘藥還會產生抗性。治療類鴉片物質誘發性便秘已被納入新標靶治療藥處方。

本報告提供全球類鴉片物質誘發性便秘治療市場相關調查,彙整各劑型,各類藥物,開發平台,及各地區的趨勢,2015∼2023年的成長率,以及參與企業簡介等資料。

第1章 序論

第2章 摘要整理

第3章 類鴉片物質誘發性便秘治療市場:產業分析

  • 簡介
  • 活動影響分析
  • 疼痛
  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
  • 法律規章方案
  • 競爭環境
    • 主要企業的市場佔有率分析:2014年
  • 市場魅力度分析

第4章 市場區隔:劑型別

  • 簡介
  • 固態
  • 半固態
  • 液狀

第5章 市場區隔:各類藥物

  • 簡介
  • µ類鴉片物質受體拮抗劑
  • 氯離子通道活化劑
  • 其他

第6章 開發平台分析

  • 概要
  • 後期(第3期)
  • 早期(第1,2期)

第7章 各地區趨勢

  • 簡介
  • 各地區市場收益
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他

第8章 建議

第9章 企業簡介

  • Abbott Laboratories, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • C.B. Fleet Company, Inc.
  • COSMO Pharmaceuticals
  • Daewoong Pharmaceutical Co. Ltd.
  • 武田藥品工業株式會社
  • Valeant Pharmaceuticals International, Inc.
目錄

This report on the opioid induced constipation treatment market studies the current and future scenario of the global market. Large number of chronic pain sufferers is responsible for rising opioid consumption. Severe chronic constipation is a major side effect of consumption of opioid and shows resistance to traditional laxatives. Hence, novel targeted therapy has been prescribed to treat opioid induced constipation. Rising number of OIC sufferers, launch of targeted medicines, and growing awareness about the therapy are the major drivers of the market.

The opioid induced constipation treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on the dosage form of the drug, type of drug class, and their geographical analysis. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises regulatory framework for major countries and event impact analysis. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global opioid induced constipation treatment market.

Based on dosage form of the drug, the market has been segmented into three major forms: solid, semi-solid, and liquid. The market segments have been analyzed based on available approved drugs for treatment and their dosage forms, cost-effectiveness, and preference for dosage form by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year.

Based on drug class, the opioid induced constipation treatment market has been segmented into three major categories based on their mechanism of action: mu opioid receptor antagonist (Movantik and Relistor), chloride channel activator (Amitiza), and others (Resolor and traditional medicines). The market segments have been extensively analyzed based on efficacy, cost, revenue, number of launched drugs, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year.

Pipeline analysis has also been provided in the report. The market has been estimated for drugs that are in phase III (late stage) clinical trials. Presently, Naldemedine is an under NDA review. A tabular representation has been included for phase II and phase I drugs.

Geographically, the global opioid induced constipation treatment market has been categorized into five major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, France, and Rest of Europe), Asia Pacific (Australia, Japan, South Korea, and Rest of Asia Pacific), Latin America (Brazil and Rest of Latin America) and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions.

The report also profiles major players in the global opioid induced constipation treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., and Cosmo Pharmaceuticals.

The global opioid induced constipation treatment market has been segmented as follows:

Global Opioid Induced Constipation Treatment Market Revenue, by Dosage form of Drugs, 2013-2023 (US$ Mn)

  • Solid
  • Semisolid
  • Liquid

Global Opioid Induced Constipation Treatment Market Revenue, by Drug Class, 2013-2023 (US$ Mn)

  • mu-opioid receptor antagonist
  • Chloride channel activator
  • Others

Global Opioid Induced Constipation Treatment Market Revenue, by Pipeline, 2013-2023 (US$ Mn)

  • Late Stage (phase III) candidates (forecast from the year of approval till 2023) (US$ Mn)
    • Naldemedine
    • Others
  • Early Stage (phase II and phase I) candidates (tabular representation)
    • Axelopran
    • Others

Global Opioid Induced Constipation Treatment Market Revenue, By Geography, 2013-2023 (US$ Mn)

  • Overview
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia Pacific
    • Australia
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Rest of the World

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Research Methodology
  • 1.3. Market Segmentation

2. Executive Summary

  • 2.1. Market Snapshot

3. Opioid Induced Constipation Treatment Market - Industry Analysis

  • 3.1. Introduction
  • 3.2. Event Impact Analysis
  • 3.3. Pain
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
  • 3.5. Regulatory Scenario
  • 3.6. Competitive Landscape
    • 3.6.1. Market Share Analysis of Key Players, 2014 (Value %)
  • 3.7. Market Attractiveness Analysis of Global Opioid Induced Constipation Treatment Market, by Geography, 2014

4. Market Segmentation - By Dosage Form of the Drug

  • 4.1. Introduction
  • 4.2. Global Solid Dosage Form Market Revenue, 2013-2023 (US$ Mn) and Analysis
  • 4.3. Global Semi-solid Dosage Form Market Revenue, 2013-2023 (US$ Mn) and Analysis
  • 4.4. Global Liquid Dosage Form Market Revenue, 2013-2023 (US$ Mn) and Analysis

5. Market Segmentation - By Drug Class

  • 5.1. Introduction
  • 5.2. Global Mu Opioid Receptor Antagonist Market Revenue, 2013-2023 (US$ Mn) and Analysis
  • 5.3. Global Chloride Channel Activator Market Revenue, 2013-2023 (US$ Mn) and Analysis
  • 5.4. Global Others Market Revenue, 2013-2023 (US$ Mn) and Analysis

6. Pipeline Analysis

  • 6.1. Overview
  • 6.2. Late Stage (Phase III)
    • 6.2.1. Naldemedine
    • 6.2.2. Others
  • 6.3. Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)

7. Market Segmentation - By Geography

  • 7.1. Introduction
  • 7.2. Global Opioid Induced Constipation Treatment Market Revenue, by Region, 2013-2023 (US$ Mn)
  • 7.3. North America Opioid Induced Constipation Treatment Market Revenue, by Country, 2013-2023 (US$ Mn)
    • 7.3.1. U.S. Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
    • 7.3.2. Canada Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
  • 7.4. Europe Opioid Induced Constipation Treatment Market - Revenue, by Country, 2013-2023 (US$ Mn)
    • 7.4.1. U.K. Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
    • 7.4.2. Germany Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
    • 7.4.3. France Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
    • 7.4.4. Rest of Europe Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
  • 7.5. Asia Pacific Opioid Induced Constipation Treatment Market Revenue, by Country, 2013-2023 (US$ Mn)
    • 7.5.1. Australia Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
    • 7.5.2. Japan Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
    • 7.5.3. South Korea Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
    • 7.5.4. Rest of APAC Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
  • 7.6. Latin America Opioid Induced Constipation Treatment Market Revenue, by Country, 2013-2023 (US$ Mn)
    • 7.6.1. Brazil Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
    • 7.6.2. Rest of Latin America Opioid Induced Constipation Treatment Market Revenue, 2013-2023, (US$ Mn)
  • 7.7. Rest of the World Opioid Induced Constipation Treatment Market Revenue, by Country, 2013-2023 (US$ Mn)

8. Recommendations

9. Company Profiles

  • 9.1. Abbott Laboratories, Inc.
  • 9.2. AstraZeneca plc
  • 9.3. Bayer AG
  • 9.4. Boehringer Ingelheim GmbH
  • 9.5. C.B. Fleet Company, Inc.
  • 9.6. COSMO Pharmaceuticals
  • 9.7. Daewoong Pharmaceutical Co. Ltd.
  • 9.8. Takeda Pharmaceutical Co., Ltd.
  • 9.9. Valeant Pharmaceuticals International, Inc.
Back to Top